PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 21, 2026Portuguese Journal of Dermatology and Venereology0 citationsOpen Access

JAK Inhibitors for Atopic Dermatitis and Comorbid Immune Diseases

JAK inhibitors for atopic dermatitis with comorbid immune diseases: a therapeutic option?

View Full Paper

Authors

MMMélissa Mendes-LopesMVMargarida Moura Valejo-Coelho

Discussion

Loading...

Member takes

Overview

Case reports illustrate JAK inhibitors improving atopic dermatitis in patients with comorbid conditions, suggesting therapeutic potential.

Key Points

  • The research aims to explore the effectiveness of JAK inhibitors like upadacitinib in treating atopic dermatitis with coexisting immune diseases.
  • Reported two cases of severe atopic dermatitis with comorbid Crohn's disease and axial spondyloarthritis.
  • Evaluated treatment response following failure of previous therapies, including dupilumab.
  • Initiated treatment with upadacitinib after multidisciplinary evaluation.
  • Both patients experienced rapid and significant improvement in eczema severity.
  • Reduction in pruritus and associated systemic symptoms was observed.
  • Findings suggest potential benefits of JAK inhibitors in managing overlapping inflammatory conditions.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mendes-Lopes et al. (2026) studied this question.

synapsesocial.com/papers/69be35166e48c4981c67324chttps://doi.org/10.24875/pjdv.25000087
Ask AI
Helpful
Bookmark
Share
View Full Paper